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Abstract
Background: The general enhanced expression of α1-antichymotrypsin (ACT), clusterin (CLU),
α1-antitrypsin (AAT), haptoglobin β-chain (HAP), and leucine rich glycoprotein (LRG) in the sera
of patients with epithelial ovarian carcinoma (EOCa) was recently reported. In the present study,
we compared the expression of the serum acute-phase proteins (APPs) in the patients according
to their stages of cancer.
Results: Different altered stage correlative expression of the high abundance serum APPs was
demonstrated in sera of the patients studied. While the expression of ACT, HAP and AAT
appeared to demonstrate positive correlation with the three initial stages of the cancer, inverse
correlation was apparently detected in the expression of LRG and CLU. For patients who were
diagnosed with stage IV of the cancer, expression of the serum APPs did not conform to the altered
progression changes.
Conclusion: Our results highlight the potential prognostic significance of selective high abundance
serum APPs in patients with EOCa.
Background
Epithelial ovarian carcinoma (EOCa) is usually asympto-
matic in its early stages and development. For most
patients, the disease is often widespread at the time of
diagnosis, and this is partly due to the absence of sensitive
and reliable serological markers. CA125, the currently
accepted serum marker for diagnosis of EOCa, is limited
in sensitivity as it is detected in approximately 50% of
patients in stage I of the disease, and 80% of women with
advanced cancer [1]. Moreover, it lacks specificity as it is
also elevated in 30% of nonovarian malignancies, 6% of
benign gynecologic disorders, and 1% of normal cases [2].
In addition, several gynecological disorders such as ovar-
ian cysts, uterine leiomyomas, pelvis inflammatory dis-
ease and endometriosis produce higher levels of CA125
[3,4].
Advances in proteomics analysis have generated much
interest in the prospect of identifying complementary
biomarkers for diagnoses of various cancers [5]. Our gel-
based proteomic studies performed on unfractionated
whole serum samples of patients with different types of
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cancer had demonstrated the different altered expression
of selective serum high abundance acute-phase proteins
(APPs) in sera of patients with EOCa [6], germ-line ovar-
ian carcinoma [6], breast cancer [7], nasopharyngeal car-
cinoma [8], endometrial adenocarcinoma [9], squamous
cell cervical carcinoma [9], adenocervical carcinoma [9]
and osteosarcoma [10]. In the case of EOCa, enhanced
expression of α1-antichymotrypsin (ACT), clusterin
(CLU),  α1-antitrypsin (AAT) and its fragments (AATf),
haptoglobin β-chain (HAP) as well as its cleaved frag-
ments (HAPc) and leucine rich glycoprotein (LRG) was
detected in serum samples of the cancer patients com-
pared to control individuals.
In the present study, the expression of the overexpressed
high abundance acute-phase proteins (APPs) in sera of the
EOCa patients was analysed according to the stages of the
cancer.
Methods
Serum samples
Serum samples were obtained from newly diagnosed
EOCa patients (ages between 24 to 65 years) in different
stages of the cancer (stage I, n = 4; stage II, n = 6; stage III,
n = 6; stage IV, n = 4) at the University of Malaya Medical
Centre (UMMC), prior to treatment. Staging of EOCa was
performed in accordance with the International Federa-
tion of Gynecology and Obstetrics (FIGO) clinical staging
system. Control sera were obtained from 24 age-matched
voluntary women without cancer. Samples obtained were
with consent and approval granted by the Ethical commit-
tee (Institutional Review Board) of the UMMC in accord-
ance with the Declaration of Helsinki and the ICH GCP
guideline.
Two-dimensional gel electrophoresis
Two-dimensional gel electrophoresis (2-DE) was per-
formed as previously described [6-10]. Unfractionated
whole human serum samples (10 μl) were subjected to
isoelectric focusing in rehydrated precast immobilized dry
strips pH 47 (GE Healthcare Bio-Sciences, Uppsala, Swe-
den). Focused samples in the strips were then subjected to
electrophoresis using 818% gradient polyacrylamide gels
in the presence of sodium dodecyl sulfate (SDS-PAGE).
All samples were analyzed in duplicate.
Staining of 2-DE gels
The 2-DE gels were developed by silver staining as
described by Heukeshoven and Dernick [11]. For mass
spectrometric analysis, gels were stained with Coomassie
Blue according to the modified method of Shevchenko et
al. [12].
Identification of proteins and database search
Confirmation on the identities of the APP spot clusters by
mass spectrometry using the Ettan MALDI-ToF Pro had
been previously described [6-9]. Peaklist data obtained
from PMF were generated using the Ettan MALDI software
(release version 2.0) and 4000 Series Explorer software
(release version 3), respectively. The data were exported to
the MASCOT search engine (Matrix Science Ltd., London,
UK; release version 2.2). The following parameters were
used in the search: (i) enzyme: trypsin, (ii) one missed
cleavage allowed, (iii) taxonomy limited to Homo sapiens,
(iv) mass value: monoisotopic, (v) peptide mass toler-
ance: ± 0.1 Da and (vi) peptide charge state: 1+.
Image analysis
Images of the 2-DE gels were captured using the LabScan
image scanner (Version 5). Protein profiles were evaluated
using the ImageMaster™ 2D Platinum Software (Version
5). To eliminate possible variations due to differential
protein staining and loading, expression of proteins was
evaluated in percentage of volume contribution (%vol),
which refers to the volume percentage of a protein taken
against the total spot volume of all proteins.
Statistical analysis
Levels of proteins in the gels are presented as means %vol
± SD of the respective number of samples in each cohort
of patients or controls analysed. The Normal test (Z) was
used to analyze the significance of differences between
control subjects and patients and to examine the correla-
tion between variables. A P-value of less than 0.05 (p <
0.05) was considered statistically significant.
Results
Serum protein profiles
Subjecting unfractionated serum samples of EOCa
patients and negative control female subjects to 2-DE and
silver staining generated typical highly resolved profiles of
the high abundance proteins. Fig. 1 demonstrates the rep-
resentative 2-DE serum protein profiles of the negative
control women (panel A) and EOCa patients in various
stages of the disease (panels B-E). Confirmation of the
identities of the various serum high abundance APPs had
been described in our previous reports [6-9]. ACT, AAT,
LRG, CLU and HAP spots clusters were clearly resolved in
all profiles. However, HAPc and AATf appeared to be
detected only in the sera of the EOCa patients but not in
control individuals, while CLU was only detected in sera
of patients in stages I and II (panels B and C, respectively),
but not those in stages III and IV, and the negative control
women.
Image analysis of 2-DE gels
When the clusters of the high abundance serum protein
spots from control women and cohorts of patients diag-Journal of Hematology & Oncology 2009, 2:37 http://www.jhoonline.org/content/2/1/37
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Typical 2-DE serum protein profiles of negative control women and patients in different stages of EOCa Figure 1
Typical 2-DE serum protein profiles of negative control women and patients in different stages of EOCa. 
Unfractionated serum samples of patients and negative controls were subjected to 2-DE and silver staining. Panel A demon-
strates a typical representative 2-DE serum protein profile of negative control women. Panels B, C, D and E demonstrate typi-
cal representative unfractionated serum protein profiles of the patients with EOCa in stages I, II, III and IV, respectively. For all 
panels, the acidic sides of the 2-DE gels are to the left and relative molecular mass declines from the top.
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nosed with different stages of EOCa were analyzed by
densitometry software, the correlative stage associated
expression of the APPs was demonstrated in sera of the
patients studied. An inverse correlation with the initial
three stages of the cancer was apparently detected in the
expression of CLU and LRG (Fig. 2, panels A and B, respec-
tively). However, the expression of ACT, HAP and AAT
appeared to be increasing with the first three stages of
EOCa (Fig. 2, panels C, D and E, respectively). For patients
who were diagnosed with stage IV of the cancer, expres-
sion of the serum APPs did not conform to the altered
progression changes. The expression of HAPc and AATf
did not demonstrate any correlation with all stages of
EOCa (Fig. 2, panels F and G, respectively). The relative
expressions (fold changes and statistical significance) of
the serum high abundance proteins in EOCa patients
according to the stage of cancer are summarized in Table
1.
Discussion
The results of our experiments highlight the potential
prognostic significance of several aberrantly expressed
APPs, and hence, the need to conduct a study to monitor
the expression of the serum proteins with progress of
EOCa. In the present study, we demonstrated the correla-
tive expression of ACT, CLU, HAP, AAT and LRG in
patients with EOCa in accordance to the three initial
stages of the cancer by using the gel-based proteomics
approach. However, the stage-correlated expression was
not observed for HAPc and AATf, although the protein
fragments were generally not detected in the 2-DE protein
profiles of normal control women. Unlike the initial three
stages of EOCa, the expression of ACT, CLU, HAP, AAT
and LRG in sera of EOCa patients in stage IV did not con-
form to the altered progression changes observed. This
was not unexpected, as the APPs response is generally
expected to succumb to the malignancy at the final stage
of the cancer, and thus affecting their synthesis in the liver.
Depending on severity of the malignancy and liver dam-
age in the late stage patients, the levels of the APPs may or
may not correlate with the patterns of the altered progres-
sion changes.
The correlative expression of high abundance serum APPs
that were detected in the present study may be reflective of
the acute-phase response of the body at various initial
stages of EOCa. The up-regulated expression of CLU in
early stages of EOCa may function to suppress the biolog-
ically aggressive behavior of the cancer cells and to exert a
protective function on surviving cells. CLU has been
reported to confer protection against various cytotoxic
agents such as UV radiation, heat shock, oxidative stress,
TNFα and chemotherapeutic drugs [13-15]. In cases of the
non small cell lung and breast cancers, the expression of
CLU was demonstrated to be significantly associated with
relapse-free and metastasis-free survival of patients
[16,17]. Taken together with the data of our present study,
this is suggestive of the prognostic significance of CLU in
the cancers concerned.
Like CLU, our present study demonstrated that the
enhanced expression of LRG appeared to be inversely cor-
related with progression of EOCa. LRG, whose function is
unknown, was consistently elevated in sera of patients
with bacterial infections and often increased during viral
infections [18]. Patients with severe acute-phase respira-
Table 1: Relative expression of APPs in the sera of patients in different clinical stages of EOCa.
Serum proteins *Fold changes and statistical significance Probability P
Stage I Stage II Stage III Stage IV
CLU # # nd nd 0.0004
LRG +23.36-fold;
p = 0.0001
+16.46-fold;
p = 0.0001
+6.44-fold;
p = 0.0001
+15.34-fold;
p = 0.0128
0.0001
ACT +2.65-fold;
p = 0.0001
+3.94-fold;
p = 0.0006
+5.50-fold;
p = 0.0001
ns 0.2177
HAP +2.24-fold;
p = 0.0001
+2.84-fold;
p = 0.0004
+6.78-fold;
p = 0.0001
ns 0.0001
AAT +2.52-fold;p = 0.0001 +3.35-fold;p = 0.0001 +4.09-fold;p = 0.0001 +4.75-fold;p = 0.0001 0.0008
HAPc #### 0 . 0 7 5 7
AATf +7.30-fold;
p = 0.0001
+8.91-fold;
p = 0.0001
+8.12-fold;
p = 0.0001
+14.14-fold;
p = 0.0001
0.0388
*Fold change measures the degree of change in protein expression in patients compared to that of negative controls. This is measured by dividing 
the average spot intensity in the patients by average spot intensity in the control.
# exclusive detection in patients (not detected in negative controls)
ns protein not significantly expressed
nd protein not detected
+ increased in expression
-- decreased in expressionJournal of Hematology & Oncology 2009, 2:37 http://www.jhoonline.org/content/2/1/37
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Mean percentage of volume contribution of APPs expression in negative control women and patients in different stages of  EOCa Figure 2
Mean percentage of volume contribution of APPs expression in negative control women and patients in differ-
ent stages of EOCa. Percentage of volume contribution (%vol) of APPs spot clusters were analyzed by ImageMaster™ 2D 
Platinum Software Version 5. Analysis was performed on the spot clusters of A:CLU, B:LRG, C:ACT, D:HAP, E:AAT, F:HAPc, 
and G:AATf. I, II, III and IV refer to the various stages of EOCa in patients, while NC refers to the negative control. Results are 
means ± SD of the respective number of samples in each cohort analysed (stage I, n = 4; stage II, n = 6; stage III, n = 6; stage IV, 
n = 4; negative control, n = 24). Summary of the relative expression of serum proteins analysed is presented in Table 1. Aster-
isks denote significantly different values (p < 0.05).
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tory syndrome were also noted for their enhanced levels
of serum LRG [19]. In the case of cancer, increased serum
LRG has been observed in patients with liver [20], lung
[21] and pancreatic [22] cancers. Together with HAP, it is
also one of the few high abundance cancer selective pro-
teins that were identified in a study comparing trypsin-
digested peptides of glycoproteins isolated from sera of
healthy individuals and lung adenocarcinoma patients
[23]. Aside from its potential as a biomarker for diagnosis,
the data of our present study further suggests the prognos-
tic value of LRG particularly for EOCa.
ACT is a well-established APP, whose function is primarily
associated with inflammation [24]. It's levels have previ-
ously been reported to be elevated in sera of patients with
EOCa [6], breast cancer [7], and pancreatic cancer [25,26].
Since the serine proteinase inhibitor is known to form a
complex with human kallikrein 3 (HK3; also known as
prostate-specific antigen) [27], and HK3 has been shown
to be produced by a number of tumors including the ovar-
ian tumor [28], it is very likely that the excess ACT
detected in sera of the EOCa patients was part of a com-
plex with HK3 or other proteins. However, this could not
be verified since the gel-based approach adopted in our
studies involved analysis of proteins in their denatured
forms.
The expression of HAP appeared to peak in stage III of
EOCa. A recent report by Zhao et al. also demonstrated
that circulating HAP was significantly correlated with the
stage of tumor and survival of EOCa patients [29]. These
accumulated data imply that the expression of HAP had
been affected by the tumor burden. The significant up-reg-
ulated expression of HAPc in the sera of EOCa patients in
all stages observed in the present study suggests that the
cancer associated HAP was rather unstable and prone to
proteolysis. However, the generation of HAPc did not
appear to correlate with the various stages of EOCa.
Previously reported studies performed on lung, breast and
cervical cancer patients have indicated correlative changes
in the levels of serum or plasma AAT, especially in the late
metastatic stages of the disease [30-32]. This is compatible
with the data of our present study. The significant
enhanced expression of AAT in patients with EOCa in all
stages also provides explanation to the detection of its
cleaved fragment spots, AATf, exclusively in samples from
patients. The lower molecular weight AATf was likely gen-
erated by proteolytic digestion of the abundant AAT
within the cancer microenvironment. Like HAPc, how-
ever, cleavage of the serum protein did not appear to cor-
relate with the stages of EOCa.
Conclusion
The different altered stage correlative expression of CLU,
LRG, ACT, HAP and AAT in sera of patients with EOCa
was demonstrated in the present study. Our results high-
light the potential prognostic significance of the high
abundance serum APPs in patients with EOCa.
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